Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Clinical Trials Related to Memorial Sloan Kettering Cancer Center
Related studies linked through entity extraction aliases.
Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Bicalutamide in Treating Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer
- Status
- COMPLETED
- Phase
- NA
Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma
- Status
- COMPLETED
- Phase
- N/A
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
- Status
- COMPLETED
- Phase
- PHASE2
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
- Status
- COMPLETED
- Phase
- PHASE1
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
- Status
- COMPLETED
- Phase
- PHASE1
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
- Status
- UNKNOWN
- Phase
- NA
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2